Long term efficacy of radioiodine treatment in hyperthyroidism

Experimental and Clinical Endocrinology and Diabetes

Volumn 121, Issue 8, 2013, Pages 494-497

  Bakos, B ^a   Takacs I ^a   Nagy, Z ^a   Kosa J P ^a   Balla, B ^a   Tobias B ^a   Halaszlaki C ^b   Szili, B ^a   Lakatos, P ^a  

^a SEMMELWEIS UNIVERSITY   (Hungary)

^b Department of Gastroenterology   (Hungary)

Author keywords

Graves' disease; radioiodine therapy; toxic adenoma

Indexed keywords

IODINE 131; RADIOACTIVE IODINE; THYROTROPIN;

ADULT; ARTICLE; CLINICAL EVALUATION; CONTROLLED STUDY; DRUG EFFICACY; EUTHYROIDISM; FOLLOW UP; GRAVES DISEASE; HUMAN; HYPERTHYROIDISM; HYPOTHYROIDISM; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; RECURRENCE RISK; RECURRENT DISEASE; RETROSPECTIVE STUDY; THYROID ADENOMA; THYROTROPIN BLOOD LEVEL; TOXIC GOITER;

ADULT; AGED; AGED, 80 AND OVER; FEMALE; FOLLOW-UP STUDIES; GOITER, NODULAR; GRAVES DISEASE; HUMANS; HYPERTHYROIDISM; IODINE RADIOISOTOPES; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84884156237     PISSN: 09477349     EISSN: 14393646     Source Type: Journal    
DOI: 10.1055/s-0033-1334884     Document Type: Article

References (19)

1. Wang C., Crapo L. M. The epidemiology of thyroid disease and implications for screening. Endocrinol Metab Clin North Am: 1997; 26 189
2. Nygaard B., Hegedus L., Nielsen K. G. et al. Long-term effect of radioactive iodine on thyroid function and size in patients with solitary autonomously functioning toxic thyroid nodules. Clin Endocrinol: 1999; 50 197 202 (Pubitemid 29100006)
3. Nordyke R. A., Gilbert F. I. Optimal I-131 dose for eliminating hyperthyroidism in Graves-disease. J Nucl Med: 1991; 32 411 416
4. Blomfield G. W., Eckert H., Fisher Monica et al. Treatment of Thyrotoxicosis with 131I. Br Med J: 1959; 1 63 74
5. Smith R. N., Wilson G. M. Clinical trial of different doses of 131-I in treatment of thyrotoxicosis. Br Med J: 1967; 1 129 132
6. Marinelli L. D., Quimby E. H., Hine G. J. Dosage determination with radioactive isotopes. Practical considerations in therapy and protection. Am J Roentgenol Radium Ther: 1948; 59 260 281
7. de Rooij A., Vandenbroucke J. P., Smit JW A. et al. Clinical outcomes after estimated versus calculated activity of radioiodine for the treatment of hyperthyroidism: systematic review and meta-analysis. Eur J Endocrinol: 2009; 5 771 777
8. Allahabadia A., Daykin J., Sheppard M. C. et al. Radioiodine treatment of hyperthyroidism - Prognostic factors for outcome. J Clin Endocrinol Metab: 2001; 86 3611 3617 (Pubitemid 32755951)
9. Boelaert K., Syed A. A., Manji N. et al. Prediction of cure and risk of hypothyroidism in patients receiving I-131 for hyperthyroidism. Clin Endocrinol: 2009; 70 129 138
10. Filesi M., Travascio L., Montesano T. et al. The relationship between 24 h/4 h radioiodine-131 uptake ratio and outcome after radioiodine therapy in 1402 patients with solitary autonomously functioning thyroid nodules. Ann Nucl Med: 2009; 23 229 234
11. Bajner Á. Radiojód-terápia pajzsmirigy- autonómiában: kezdeti eredményeink, tapasztalataink. Orv Hetil: 2008; 18 839 842 (Pubitemid 351772166)
12. Metso S., Jaatinen P., Huhtala H. et al. Long-term follow-up study of radioiodine treatment of hyperthyroidism. Clin Endocrinol: 2004; 61 641 648 (Pubitemid 39540368)
13. Calegaro JU M., Gomes E. D., Bae S. H. et al. One-year follow-up of Graves' disease treatment by four different protocols of radioiodine administration. Panminerva Med: 2000; 42 241 245
14. Peters H., Fischer C., Bogner U. et al. Treatment of Graves' hyperthyroidism with radioiodine: Results of a prospective randomized study. Thyroid: 1997; 7 247 251 (Pubitemid 27190591)
15. Konrády A. A jóindulatú pajzsmirigybetegségek radiojód kezelése. Orv Hetil: 2006; 37 1783 1789
16. de Bruin T. W., Croon CD L., Deklerk JM H. et al. Standardized radioidine therapy in Graves-Disease - The persistent effect of thyroid weight and radioiodine uptake on outcome. J Intern Med: 1994; 236 507 513 (Pubitemid 24340007)
17. Tuttle R. M., Patience T., Budd S. Treatment with propylthiouracil before radioactive iodine therapy is associated with a higher treatment failure rate than with radioactive iodine alone in Graves-disease. Thyroid: 1995; 5 243 247
18. Akamizu T., Moti T., Kasagi K. et al. Anti-TSH antibody with high specificity to human TSH in sera from patients with Graves' disease: its isolation from, and interaction with, TSH receptor antibodies. Clin Endocrinol: 1987; 26 311 320 (Pubitemid 17018995)
19. Cholewinski W., Nocun A., Stefaniak B. et al. The influence of 131I-radioiodine therapy on anti-TSH antibody level measured with TRAK-HUMAN kit. Eur J Nucl Med Mol Imaging: 2002; 29 S343